AUS
NZ
UK
CA
USA
IND
Highlights
Tryp Therapeutics Ltd (ASX:TYP, OTC:TYPTF) collaborates with Swinburne University for a pioneering trial addressing Binge Eating Disorder
The study will utilise TRP-8803, a proprietary psilocin formulation, alongside psychotherapy
The trial follows previous studies showing reduced binge episodes using earlier psilocybin-based treatments
Tryp Therapeutics Ltd, operating in the healthcare and biotechnology sector, has commenced a collaboration with Swinburne University of Technology to launch a first-of-its-kind clinical trial focused on Binge Eating Disorder (BED). The trial marks a significant clinical initiative involving the intravenous formulation TRP-8803, derived from psilocin, the active metabolite of psilocybin. This compound has been identified for its influence on neuroplasticity, mood regulation, and cognitive behavior.
The upcoming study is structured to combine pharmaceutical and psychological interventions to evaluate a new treatment pathway in addressing BED, a condition that has shown resistance to traditional methods. This effort reinforces the continued role of therapeutic psychedelics in mental health research.
Trial Overview and Methodology
The clinical trial is designed as an open-label study assessing the safety, feasibility, and tolerability of TRP-8803 when administered in conjunction with psychological support. The trial will initially involve a small group of adult participants who will each undergo a structured dosing regimen under clinical supervision.
Participants will be divided into two groups and each will receive two administrations of TRP-8803 spaced over a fixed interval. Each group will be assigned distinct dose ranges—classified as mid-range and high-range—to evaluate response variations. All treatments will occur in a medical setting and will be monitored by experienced clinical staff.
The research will be led by Professor Susan Rossell, a recognised cognitive neuropsychologist from Swinburne’s Centre for Mental Health. This partnership leverages both academic and therapeutic expertise to advance the understanding of psychedelic-assisted interventions for eating disorders.
Background and Previous Research Outcomes
TRP-8803 builds on data generated from earlier research involving TRP-8802, an oral psilocybin-based formulation previously examined in clinical settings. That study, undertaken by the University of Florida, reported positive outcomes in reducing disordered eating behaviors in participants.
Given the widespread occurrence of BED, particularly in individuals with coexisting conditions such as anxiety, depression, PTSD, and sleep-related issues, this study seeks to contribute new insights to the clinical literature. The disorder remains the most frequently diagnosed eating condition in several regions and lacks approved pharmacological treatments specifically developed for its management.
Clinical Expansion and Development Strategy
Tryptamine Therapeutics Ltd (ASX:TYP) has indicated plans to expand its clinical programs by applying the TRP-8803 formulation in studies targeting a broader range of neuropsychiatric diagnoses. These trials are under development and aim to generate unique clinical data supporting future therapeutic approvals.
The protocol developed in collaboration with Swinburne University reflects a strict adherence to quality control and regulatory standards. The initiative is designed to contribute to the advancement of healthcare stocks and pharmaceutical innovation within the ASX 200 index.
In preparation for future trials, additional protocols are in the final stages of planning. These efforts will be informed by data obtained from this BED-focused trial, further refining clinical pathways for psychedelic-assisted therapies.
Understanding Binge Eating Disorder
BED is frequently associated with psychological comorbidities and is notably prevalent among individuals seeking treatment for weight-related conditions. The complexity of BED, including its emotional and behavioral components, presents challenges for conventional therapies.
Through its current and upcoming research, Tryp Therapeutics Ltd (ASX:TYP) continues to contribute to a deeper understanding of psychiatric treatment development, particularly in segments that intersect with metabolic, psychological, and neurological health.
